Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Early Environmental quality and life-course mental health effects (Equal-Life)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Preventing disease
Action type: Research and Innovation actions
Countries involved: Austria,Germany,Germany,Germany,Spain,Spain,Germany,Italy,Belgium,Finland,Finland,Sweden,Sweden,North Macedonia,Slovenia,Netherlands,Netherlands,Netherlands,Netherlands,Netherlands,United Kingdom
Call: The Human Exposome Project: a toolbox for assessing and addressing the impact of environment on health (H2020-SC1-2019-Single-Stage-RTD, 2019)
Start date: 2020-01-01
End date: 2024-12-31
Duration (months): 60.0
Total project cost (EUR): 11997926.25
EU funding (EUR): 11994426.25
Participants: 22
Project status: SIGNED

EQUAL-LIFE will develop and test combined exposure data using a novel approach to multi-modal exposures and their impact on children’s mental health and development. A combination of birth-cohort data with new sources of data, will provide insight into aspects of physical and social exposures hitherto untapped. It will do this at different scale levels and timeframes, while accounting for the distribution of exposures in social groups based on gender, ethnicity, social vulnerability. Beginning with child development and mental health, a set of theory-based questions is formulated, a wide range of relevant environmental and social hazards is defined and validated at the stakeholders end. Exposure assessment combines traditional GIS-based approaches with omics approaches and new sources of data that could explain aspects of the urban environment at a higher spatial and temporal granularity, and provide insight into untapped parameters relating to exposure (spatial quality of neighborhoods). These together form the early-life exposome. Statistical tools integrate data at different scale levels and times and combine e.g. machine learning, causal models with subgroups measures. EQUAL-LIFE uses data from birth-cohorts, longitudinal school data sets and cross-sectional studies (N=>250.000), including data on exposures, biomarkers, mental health and developmental outcomes, in their social context. EQUAL-LIFE contributes to the development/utilization of the exposome concept by 1) integrating the internal, external and social exposome 2) by studying a distinct set of effects on a child’s development and mental health 3) by characterizing/measuring/modelling the child’s environment at different stages and activity spaces 4) by looking at supportive environments for child development, rather than merely pollutants 5) by combining physical, social indicators with novel biomarkers and using new data sources describing child activity patterns and environments. EQUAL-LIFE is part of the European Human Exposome Network comprised of nine projects selected from this same call.

Keywords: exposome,physical and social environment,early childhood,mental health,sleep,restorative environments,cognitive development,social development
Here be Spiral DRAGNs (Spiral DRAGNs)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Physics
Countries involved: United Kingdom
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2014, 2014)
Start date: 2016-05-01
End date: 2018-10-28
Duration (months): 24.0
Total project cost (EUR): 183454.8
EU funding (EUR): 183454.8
Participants: 1
Project status: CLOSED

Until recently, it was thought that large double-lobed radio sources are always hosted by massive elliptical galaxies in the local Universe and that the merger phenomenon responsible for the elliptical morphology is also responsible for triggering the AGN. Consequently, the existence of spiral galaxies that host double-lobed radio sources (“spiral DRAGNs”) is inconsistent with leading galaxy formation models. However, these systems have been confirmed to exist, calling into question our current understanding of galaxy formation. This project aims to establish the role of these systems in galaxy formation: either reconciling their existence with current models or challenging the idea of the standard feedback model. I propose a multi-pronged approach to this project: First, I will study the parsec-scale environment in the immediate vicinity of the AGN and determine whether properties of the central black hole in these spiral hosts are similar to those of the black holes hosted by elliptical galaxies; Second, I will study the megaparsec-scale environment of spiral DRAGNs to determine whether their environment is responsible for their unique nature. I will achieve the first science goal using Very Long Baseline Interferometry (VLBI) radio observations. I will achieve the second science goal using a combination of archival and new data at multiple wavelengths. Together these two science goals will enable us to definitively determine whether spiral DRAGNs are a result of the intrinsic properties of the black hole, a result of their large-scale environment, or a combination of both these factors. Furthermore, I will exploit my role as lead for the Radio Galaxy Zoo project on spiral DRAGNs to find more of these sources. To-date there have been only four spiral DRAGNs detected. Increasing the sample size is imperative for testing the hypotheses that will be formed in the above two science goals, and enable statistically significant conclusions to be drawn.
Big Data and models for personalized Head and Neck Cancer Decision support (BD2Decide)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Methods and data
Action type: Research and Innovation actions
Countries involved: Germany,Spain,Italy,Italy,Germany,Israel,Greece,Netherlands,Netherlands
Call: Digital representation of health data to improve disease diagnosis and treatment (H2020-PHC-2015-single-stage, 2015)
Start date: 2016-01-01
End date: 2019-09-30
Duration (months): 45.0
Total project cost (EUR): 4845000.0
EU funding (EUR): 4845000.0
Participants: 13
Project status: CLOSED

Cancers of the Head and Neck Region (HNC) are the 6th more deadly cancers worldwide: in Europe ~150.000 new cases are detected and ~70.000 patients die every year. The main reasons for high mortality are the fact that the majority of cases are diagnosed in advanced Stage and the intrinsic heterogeneity of such tumors. At present the only adopted treatment decision method is based on TNM (Tumor-lymph-Nodes-Metastasis) prognostic system, that considers only a few risk factors such as smoking, alcohol abuse and more recently HPV. The TNM system is therefore inadequate to capture the patient-specific biomolecular characteristics of the tumor. HNC treatments can have hard impact on patient’s aesthetics and functionalities and, due to their toxicity, can cause severe morbidity and greatly deteriorate patient’s quality of life. A more precise prognostic prediction than the current TNM system is needed that allows implementing the first-line treatment that maximizes the therapeutic result and minimizes the impacts of therapy. BD2Decide DSS provides clinicians with the "means" and all the necessary information to tailor treatment and care delivery pathway to each and any HNC patient during their usual practice, in contrast to current “one-size-fits-all approach”. BD2Decide realizes and validates an Integrated Decision Support System that links population-specific epidemiology and behavioral data, patient-specific genomic, pathology, clinical and imaging data with big data techniques, multiscale prognostic models. Advanced graphical visualization tools are developed for prognostic data disclosure and patient co-participation to the selected treatment. BD2Decide will improve the clinical decision process, uncover new patient-specific patterns that can improve care, and create a virtuous circle of learning. A multicentric clinical study with more than 1.000 patients will be used to validate the system.

Keywords: predictive models,oral cancer
Establishing services enhancing the innovation management capacity of Hungarian SME's in the Enterprise Europe Network (INNO-HUN2014)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: Coordination and support actions
Countries involved: Hungary,Hungary,Hungary,Hungary
Call: INNOSUP (H2020-Adhoc-2014-20, 2014)
Start date: 2014-10-01
End date: 2014-12-31
Duration (months): 3.0
Total project cost (EUR): 16813.75
EU funding (EUR): 13451.0
Participants: 4
Project status: CLOSED

Establishing services enhancing the innovation management capacity of Hungarian SME's in the Enterprise Europe Network The global objective of the services delivered under this project is to effectively contribute to the innovation driven competitiveness and sustainable growth of the European economy via improving the innovation management processes in SMEs enabling them to get their products, services successfully on the market. The concept of this project focuses on the development of Innovation Management capabilities via two different types of high-added value services: • “Key account management” for the beneficiaries of the SME Instrument • “Enhancing SME innovation management capacity” provided independently from a specific project to innovating SMEs with a clear potential to go international

Keywords: enterprise europe network,sme instrument,key account management,enhancing sme innovation management capacity,innovation management,smes
Development of replacement method for all kind of 16g dynamically tested aircraft cushions. (16gAirTest)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Action type: SME instrument
Countries involved: Italy
Call: Small business innovation research for Transport (H2020-SMEINST-1-2014, 2014)
Start date: 2014-10-01
End date: 2015-02-28
Duration (months): 5.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Airline operators are faced with increased need to replace passengers seat cushions, certified for security standards at sustainable retrofit costs. Since October 2009, the Federal Aviation Administration (FAA) regulation 121-135 has imposed more strict standards for aircraft seats, which must sustain a load of 16g in forward direction and 14g in down direction. As a consequence airlines need to gradually replace current "9g seats" (approx. 65% of current aircraft seats) with new ones compliant with the 16g standard. At present the 16g certification requires testing of the entire seat, which may cost up to 1,3 K€/pax. while a new certified cushion may cost 200-250 €. The aircraft cushions and seats market is almost totally occupied by a few manufacturers who keep prices high, especially when the original cushion model is phased-out and either the entire seat must be replaced, or costly custom-made cushions produced. Consequently many airlines avoid replacement or adopt non-standard cushions, despite risks for passengers' safety. Testori Aero Supply has achieved a EASA approval for a certification method for 16g monolithic cushions, and has already produced such replacement cushions for a client on a Boeing B777. At present Testori is the only independent company holding this qualification. This project intends to exploit this method to the certification of 16g multilayer cushions, and to produce and sell them at a competitive price of 200-250€. The feasibility study will assess the market positioning, the industrialization and production costs, the market demand and the market potential for the company, taking into consideration the customers (airline operators) and the aircraft fleets (current and new) in the areas where Testori already successfully operates. The project will open new business in airplane retrofit market for Testori and increase competitiveness for European SMEs operating in this field.

Keywords: air transport,passengers safety,airplane seats certification
Magneto-Plasmonic, Raman active Nanocapsules for Superior Pediatric Brain Cancer Therapy (SUPERBRAIN)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: United Kingdom
Call: Individual Fellowships (H2020-MSCA-IF-2018, 2018)
Start date: 2020-09-01
End date: 2022-08-31
Duration (months): 24.0
Total project cost (EUR): 224933.76
EU funding (EUR): 224933.76
Participants: 1
Project status: CLOSED

Advances in neurosurgery, radio-chemotherapy resulting in improved survival/cure rates for children with brain tumors. Nevertheless, after domestic accidents, cancer remains the second leading cause of death in children with the overall 5-year survival statistic of 15-35%. Central nervous system (CNS) tumors are the second most diagnosed cancer in pediatric oncology. Radio-chemotherapy protocols for CNS cancers limiting therapeutic potential due to long-term concerns of radiation exposure and late adverse effects of chemotherapy in developing children. The battle against pediatric cancer is potentially much more effectively fought if the therapy is concurrent with diagnosis and monitoring modalities. SUPERBRAIN develops a multifunctional nanocomposite termed as nanocapsule that enables a simultaneous diagnosis, therapy and treatment monitoring (theranostics). It introduces a new paradigm of theranostics combines tumor targeting biomolecule (aptamer), chemotherapeutic cargo, Surface Enhanced Raman Spectroscopy (SERS) coupled with magnetic resonance imaging (MRI) and photothermal therapy to combat pediatric CNS cancer. We elaborate multimodality in one nanocapsule by decorating magnetic nanoparticles with plasmonic shell functionalized with chemotherapeutic drugs and CNS cancer cell targeting aptamer and magnetically guided nanocapsules in vivo delivery. Furthermore, non-destructive SERS together with Raman microscopic techniques is introduced here for rapid identification of a cancer cells ‘molecular fingerprint’ allowing visualization of brain tumor margins. Additionally, application of MRI for visualizing 3D brain anatomy is providing opportunity of therapy monitoring. These bioengineered nanocapsules can then be stimulated by near infrared (NIR) light for minimally invasive photonic excitation (photothermal therapy). Finally, we will demonstrate >99% killing of CNS brain tumor tissues (in vitro and in vivo) with this new paradigm as a gold standard theranostics.

Keywords: biomedical nanotechnology,magnetic nanoparticles,photothermal effect,raman spectroscopy,imaging,cancer therapy
Decarbonising Transport – Driving implementation actions (DTImplement)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Action type: Coordination and support actions
Countries involved: France
Call: Strengthening international policy dialogue to address global challenges: the contribution of transport research & innovation (H2020-IBA-SC4-Dialogue-2020, 2020)
Start date: 2021-03-01
End date: 2023-02-28
Duration (months): 24.0
Total project cost (EUR): 1000000.0
EU funding (EUR): 1000000.0
Participants: 1
Project status: CLOSED

In the context of this project, the ITF will set up fora for EU member states, OECD member countries and all key transport stakeholders to identify transport R&I priorities of common interest. This will help to support the transfer of innovative transport and mobility solutions into concrete policy actions and create a favourable environment for the implementation of sustainable and inclusive transport policies. The project will focus especially on innovative transport and mobility solutions that are capable to improve energy efficiency and reduce emissions of CO2 and local pollutants in the transport sector while being socially fair, fostering social inclusiveness and economic progress. The project will gather quantitative information allowing to characterise these solutions, it will consider barriers for their development and adoption and it will identify policy instruments available to effectively overcome them, leveraging on data, experiences and lessons that involve countries and other stakeholders leading the action on climate change mitigation and the achievement of sustainable development goals.

Keywords: decarbonising transport,sustainable transport,innovation,policy dialogue,stakeholder fora
Empowering Energy Poor Citizens through Joint Energy Initiatives (POWERPOOR)

Framework: Horizon 2020 — Societal Challenges
Programme: Secure, clean and efficient energy
Theme: Reducing energy consumption and carbon foorpint by smart and sustainable use
Action type: Coordination and support actions
Countries involved: Estonia,Germany,Spain,Belgium,Bulgaria,Greece,Croatia,Hungary,Greece,Greece,Latvia,Luxembourg,Portugal
Call: Mitigating household energy poverty (H2020-LC-SC3-EE-2019, 2019)
Start date: 2020-09-01
End date: 2023-08-31
Duration (months): 36.0
Total project cost (EUR): 1999812.5
EU funding (EUR): 1999812.5
Participants: 15
Project status: SIGNED

The main objective of POWERPOOR is to develop support programmes/schemes for energy poor citizens and encourage the use of alternative financing schemes (e.g. establishing energy communities / cooperatives, crowd funding). POWERPOOR will facilitate experience and knowledge sharing, as well as the implementation of small-scale energy efficiency interventions and the installation of renewable energy sources, increasing the active participation of citizens. Pilot energy poor support programmes/schemes will be designed, developed and implemented in eight countries across Europe, led by a network of certified Energy Supporters and Energy Communities Mentors. The Energy Supporters / Mentors will support (more than 22,000) energy poor households to plan and implement energy efficiency interventions, as well as participate in joint energy initiatives. Energy poor citizens will be engaged through various planned activities, such as Info Days, Local Energy Poverty Offices, and ICT-driven tools (Energy Poverty Mitigation Toolkit). The establishment of the Stakeholders Liaison Groups will also facilitate the engagement and the provision of support to energy poor households. Guidelines on how to tackle energy poverty in Sustainable Energy and Climate Action Plans will also be developed. Based on the experience gained and the lessons learnt from implementing POWERPOOR, EU policy recommendations and 8 National Roadmaps will be elaborated, so that policy makers at all governance levels can learn from the project. The project results will be broadly disseminated, and synergies will be pursued with global and EU initiatives, such as the EU Energy Poverty Observatory and the (EU and Global) Covenant of Mayors on Energy and Climate. The participation of networks in the Consortium will strengthen the dissemination and exploitation of POWERPOOR outputs across Europe during and beyond the project implementation.

Keywords: energy cooperatives,crowd funding,ict tools,energy supporters,mentors,capacity building,energy poor support programmes,schemes,cities,regions,social services,secaps,policy recommendations
An innovative, minimally invasive medical device used for treatment of Benign Prostatic Hyperplasia symptoms (ClearRing)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Israel
Call: SME instrument (H2020-SMEInst-2018-2020-2, 2019)
Start date: 2019-08-01
End date: 2022-01-31
Duration (months): 30.0
Total project cost (EUR): 2776750.0
EU funding (EUR): 1943725.0
Participants: 1
Project status: CLOSED

Benign Prostatic Hyperplasia (BPH), or prostate enlargement, is one of the most common urological diseases among men. As the prostate enlarges with the age, it presses on and blocks the urethra, causing bothersome urinary symptoms. Over 70% of men in their 60s have symptoms of BPH 1, and 80-90% of men over 80 year old. BPH affects around 200 million men worldwide. The current methods present a significant unmet need for minimally invasive or less invasive BPH therapy as a less costly, more tolerable, and comparatively safe alternative to drugs and invasive surgery, which carry greater risk of undesirable side effects and complications. ClearRing is a revolutionary treatment of BPH symptoms, based on a pre-shaped implant and a dedicated delivery system. The ClearRing solution is the only minimally invasive system for BPH which is implantable inside the prostate with 0% chance of migration or encrustation. It puts ProArc in a unique position as a first company providing significantly improved health conditions and quality of life. Its rapid procedure enables hospitals to get patients in and out more quickly, creating a better patient experience as well as a more efficient management of medical resources. The minimally invasive procedure reduces the range and severity of side effects allowing patients to resume their normal lifestyles potentially twice as fast as the current standard operation procedure. Furthermore, it preservers sexual function. Overall objective of ProArc is to introduce a BPH treatment which is effective, affordable and with no side-effects, therefore men seek for the treatment instead of watchful waiting for the worsening. Whereas, the key objective of the project is to validate the ClearRing safety and efficacy for BPH treatment through a randomized clinical trial at 3 medical centres. This large scale clinical validation will enable ProArc to obtain the CE mark, and gradually apply for the reimbursement authorisation.

Keywords: benign prostatic hyperplasia,prostate enlargement,prostate,minimally invasive,medical device,ageing